GLP-1 agonist drugs used to treat type 2 diabetes may also reduce the risk of colorectal cancer. This is reported by the authors of a study published in the journal. JAMA Oncology.
Obesity not only increases your cardiovascular risk, but also increases your chances of developing various types of cancer, as well as type 2 diabetes. To treat the latter, a new class of drugs is used – GLP-1 agonists. They lower blood sugar, increase insulin sensitivity and help control weight. It has also been shown to reduce the incidence of serious cardiovascular disease.
In the new study, researchers analyzed data from more than 1.2 million patients taking antidiabetic medications from 2005 to 2019. The incidence of colorectal cancer was 44% lower in people taking GLP-1 agonists than in those taking insulin and 25% lower than in those taking metformin. The protective effect of GLP-1 agonists was observed in both normal and overweight patients.
Previous scientists to create A product that reduces the activity of cancer-related genes.